Insights into leukemogenesis from therapy-related leukemia.
Pedersen-Bjergaard
Jens
J
D000970:Antineoplastic Agents / Q000009:adverse effects*; D002869:Chromosome Aberrations; D004250:DNA Topoisomerases, Type II / Q000378:metabolism*; D004273:DNA, Neoplasm / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007951:Leukemia, Myeloid / Q000139:chemically induced / Q000235:genetics; D015473:Leukemia, Promyelocytic, Acute / Q000139:chemically induced / Q000235:genetics*; D016609:Neoplasms, Second Primary / Q000139:chemically induced / Q000235:genetics*; D059005:Topoisomerase II Inhibitors; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D004273:DNA, Neoplasm; D059005:Topoisomerase II Inhibitors; D004250:DNA Topoisomerases, Type II